Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia
Biomolecules · 2024
DOI: 10.3390/biom14060644 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Vera Vysochinskaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, 194064 St. …. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, RNA, Small Interfering, Fusion Proteins, bcr-abl, Molecular Targeted Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is an oncological myeloproliferative disorder that accounts for 15 to 20% of all adult leukemia cases. The molecular basis of this disease lies in the formation of a chimeric oncogene BCR–ABL1. The protein product of this gene, p210 BCR–ABL1, exhibits abnormally high constitutive tyrosine kinase activity. Over recent decades, several targeted tyrosine kinase inhibitors (TKIs) directed against BCR–ABL1 have been developed and introduced into clinical practice. These inhibitors suppress BCR–ABL1 activity through various mechanisms. Furthermore, the advent of RNA interference technology has enabled the highly specific inhibition of BCR–ABL1 transcript expression using small interfering RNA (siRNA). This experimental evidence opens avenues for the development of a novel therapeutic strategy for CML, termed siRNA therapy. The review delves into molecular genetic mechanisms underlying the pathogenesis of CML, challenges in CML therapy, potential molecular targets for drug development, and the latest results from the application of siRNAs in in vitro and in vivo CML models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, 194064 St. Petersburg, Russia.
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Ulitsa Prof. Popova, 197376 St. Petersburg, Russia.
- Almazov National Research Centre, Akkuratova str. 2, 197341 St. Petersburg, Russia.
- Russian Academy of Sciences, 14 Leninskiy pr., 119991 Moscow, Russia.
ORCID-Profile: Michael Dubina, Andrey Vasin, Yana Zabrodskaya
Förderung
- Russian Science Foundation
Zitieren
APA
Vysochinskaya, V., Dovbysh, O., Gorshkov, A., Brodskaia, A., Dubina, M., Vasin, A., & Zabrodskaya, Y. (2024). Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia. Biomolecules. https://doi.org/10.3390/biom14060644
Vancouver
Vysochinskaya V, Dovbysh O, Gorshkov A, Brodskaia A, Dubina M, Vasin A, et al. Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia. Biomolecules. 2024. doi:10.3390/biom14060644
BibTeX
@article{Vysochinskaya2024,
author = {Vysochinskaya, Vera and Dovbysh, Olesya and Gorshkov, Andrey and Brodskaia, Alexandra and Dubina, Michael and Vasin, Andrey and Zabrodskaya, Yana},
title = {Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14060644}
}
EUVIMED